Home > Press Releases > AI in Clinical Trials Market

AI in Clinical Trials Market Likely to Surpass USD 2.7 Billion by 2035

Report Code: HC-34197 | Published in: Jul 2026, By MarketGenics | Number of pages: 358

Global AI in Clinical Trials Market Forecast 2035:

According to the report, the global AI in clinical trials market is likely to grow from USD 1.1 Billion in 2025 to USD 2.7 Billion in 2035 at a highest CAGR of 9.2% during the time period. The global market for AI in clinical trials is changing by leveraging advanced computational intelligence throughout the pharmaceutical research landscape, facilitating quicker understanding of intricate clinical data and increasing the precision of decision-making throughout multi-phase drug development cycles. This transition will help boost study design accuracy, patient selection, and prediction for future outcomes, ultimately improving trial efficiency.

Clinical research infrastructures are increasingly driven by data-unified approaches, where multiple data sources, including electronic health records, lab reports and patient-reported outcomes, are brought together into structured analytical environments. This makes it easier to see data at all stages of the trial and minimizes data management delays and manual data interpretation.

The pharmaceutical and healthcare sector is also transitioning to a digitally connected research network to share and monitor the status of ongoing clinical trials at real-time, enabling more adaptive decision making and coordination across study sites around the world, thereby enhancing operational collaboration, speeding up evidence generation and making more responsive clinical development decisions.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global AI in Clinical Trials Market”

The increasing demand to expedite drug development timelines by leveraging AI's capabilities in advanced analytics and predictive modeling is propelling the global AI in clinical trials market. AI's ability to optimize trial design, improve patient stratification, and enhance decision-making efficiency in complex clinical trial workflows is accelerating the growth of the global AI in clinical trials market. The increasing trend of cutting R&D spending and enhancing rates of success is driving another surge in the use of AI-powered clinical trial solutions.The demand for cost reduction in R&D spend, coupled with boosting success rates, is further fueling the growth of AI-powered clinical trial solutions.

Ethical considerations, the necessity of patient consent, and the intricate regulatory framework surrounding the handling of sensitive clinical data hinder the efficient exchange of information between institutions, thereby posing challenges to the seamless incorporation of AI in clinical trial workflows.Strict ethical protocols, patient consent requirements, and complex regulatory frameworks surrounding the handling of sensitive clinical data restrict the smooth integration of AI into clinical trial workflows.

New decentralized clinical trial models and platforms for integrating real-world evidence offer significant possibilities for the market, facilitating remote patient monitoring, virtual engagement, and ongoing data collection from healthcare ecosystems. The use of digital health technologies, wearable health data inputs, and cloud-based trial management platforms is likely to greatly improve trial efficiency and widen patient access across the globe.

Expansion of Global AI in Clinical Trials Market

“AI-Driven Protocol Optimization, Decentralized Patient Recruitment Systems, and Real-World Evidence Integration Platforms”

The global AI in clinical trials market is also growing with the increasing use of AI-powered trial design and protocol optimization systems, which facilitate researchers to simulate the outcomes of clinical trials, optimize eligibility criteria, and streamline the clinical trial process by minimizing patient enrollment delays and protocol modifications during complex trials.
Key market drivers are the introduction of AI-powered and decentralized platforms for patient recruitment, which use electronic health records (EHRs), digital biomarkers, and predictive patient-matching algorithms to boost participant identification accuracy and diversify and represent patients in clinical trials.
Moreover, there is an increase in the market because of the rise of integrated real-world evidence (RWE) platforms, which will enable to continuously validate trials, make better regulatory decisions, and improve therapeutic development insights that will be based on post-market patient outcomes along with the healthcare databases.

Regional Analysis of Global AI in Clinical Trials Market

The adoption of AI in clinical trials in North America is accelerating, with AI-driven protocol optimization, the increasing deployment of decentralized clinical trial (DCT) infrastructure, and the seamless integration of real-world evidence (RWE), genomic data, and electronic health records (EHRs). The region is also home to a robust biopharmaceutical services ecosystem, including contract research organizations (CROs), cloud-based clinical platforms, and providers of AI technology, which is driving intelligent trial execution and data-driven clinical development.
The Asia Pacific region is the fastest-growing region in the AI in clinical trials market, which is attributed to the growth in clinical trial outsourcing, adoption of digitalization of healthcare systems in the region, and the rising investments in AI-enabled research infrastructure across emerging economies in Asia Pacific. The region has been witnessing a robust push towards life sciences innovation, a massive patient base, and increased uptake of cloud-based clinical technologies that continue to propel the region's clinical trial activity and AI adoption forward.

Prominent players operating in the global AI in clinical trials market Amazon Web Services, Inc., Clario, ConcertAI, LLC, ICON plc, International Business Machines Corporation (IBM), IQVIA Inc., Laboratory Corporation of America Holdings (Labcorp), Medidata Solutions, Inc., NVIDIA Corporation, Oracle Corporation, Parexel International Corporation, Saama Technologies, LLC, Syneos Health, Inc., Tempus AI, Inc., Unlearn AI, Inc., Other Key Players.

The global AI in clinical trials market has been segmented as follows:

Global AI in Clinical Trials Market Analysis, by Component

Software
- Clinical Trial Management Software
- Patient Recruitment & Enrollment Software
- Clinical Data Management Software
- Trial Analytics & Predictive Modeling Software
- Safety & Pharmacovigilance Software
- Regulatory Compliance Software
- Others
Hardware
- AI Servers & High-Performance Computing (HPC) Systems
- Data Storage Systems
- Clinical Data Capture Devices
- Networking & Communication Infrastructure
- Workstations & Mobile Devices
- Others
Services
- AI Consulting & System Integration Services
- AI Deployment & Managed Services
- Clinical Data Analytics Services
- Regulatory & Compliance Services
- Technical Support & Training Services
- Others

Global AI in Clinical Trials Market Analysis, by Technology

Machine Learning (ML)
Deep Learning
Natural Language Processing (NLP)
Computer Vision
Predictive Analytics
Generative AI
Robotic Process Automation (RPA)
Big Data Analytics
Others

Global AI in Clinical Trials Market Analysis, by Deployment Mode

Cloud-Based
On-Premises
Hybrid

Global AI in Clinical Trials Market Analysis, by Clinical Trial Phase

Phase I
Phase II
Phase III
Phase IV

Global AI in Clinical Trials Market Analysis, by Therapeutic Area

Oncology
Cardiovascular Diseases
Neurology
Infectious Diseases
Immunology
Endocrinology
Respiratory Diseases
Rare Diseases
Gastroenterology
Dermatology
Others

Global AI in Clinical Trials Market Analysis, by Application

Clinical Trial Design
Patient Recruitment & Enrollment
Patient Matching
Site Selection & Feasibility
Clinical Data Management
Clinical Trial Monitoring
Risk-Based Monitoring
Protocol Optimization
Adverse Event Detection
Regulatory Compliance
Drug Safety & Pharmacovigilance
Trial Outcome Prediction
Others

Global AI in Clinical Trials Market Analysis, by End User

Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations (CROs)
Academic & Research Institutes
Hospitals & Clinical Research Centers
Government Organizations
Others

Global AI in Clinical Trials Market Analysis, by Region

North America
Europe
Asia Pacific
Middle East
Africa
South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact US

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
  - 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
  - 1.6.1. Open Sources
  - 1.6.2. Paid Databases
  - 1.6.3. Associations
- 1.7. Primary Research
  - 1.7.1. Primary Sources
  - 1.7.2. Primary Interviews with Stakeholders across Ecosystem
2. Executive Summary
- 2.1. Global AI in Clinical Trials Market Outlook
  - 2.1.1. AI in Clinical Trials Market Size (Value - US$ Bn), and Forecasts, 2021-2035
  - 2.1.2. Compounded Annual Growth Rate Analysis
  - 2.1.3. Growth Opportunity Analysis
  - 2.1.4. Segmental Share Analysis
  - 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
  - 2.5.1. Customer/ End-use Industry Assessment
  - 2.5.2. Growth Opportunity Data, 2026-2035
    - 2.5.2.1. Regional Data
    - 2.5.2.2. Country Data
    - 2.5.2.3. Segmental Data
  - 2.5.3. Identification of Potential Market Spaces
  - 2.5.4. GAP Analysis
  - 2.5.5. Potential Attractive Price Points
  - 2.5.6. Prevailing Market Risks & Challenges
  - 2.5.7. Preferred Sales & Marketing Strategies
  - 2.5.8. Key Recommendations and Analysis
  - 2.5.9. A Way Forward
3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
  - 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
  - 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
  - 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
4. Market Overview
- 4.1. Market Dynamics
  - 4.1.1. Drivers
    - 4.1.1.1. Growing adoption of AI for patient recruitment and clinical trial optimization
    - 4.1.1.2. Rising demand for decentralized and virtual clinical trials
    - 4.1.1.3. Increasing integration of real-world data (RWD) and predictive analytics in clinical research
  - 4.1.2. Restraints
    - 4.1.2.1. Data privacy, regulatory, and AI validation challenges
    - 4.1.2.2. Limited availability of high-quality, interoperable clinical datasets
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
  - 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
  - 4.3.2. Tariffs and Standards
  - 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Ecosystem Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global AI in Clinical Trials Market Demand
  - 4.7.1. Historical Market Size – Value (US$ Bn), 2020-2024
  - 4.7.2. Current and Future Market Size – Value (US$ Bn), 2026–2035
    - 4.7.2.1. Y-o-Y Growth Trends
    - 4.7.2.2. Absolute $ Opportunity Assessment
5. Competition Landscape
- 5.1. Competition structure
  - 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
  - 5.2.1. Global Company Market Share
  - 5.2.2. By Region
    - 5.2.2.1. North America
    - 5.2.2.2. Europe
    - 5.2.2.3. Asia Pacific
    - 5.2.2.4. Middle East
    - 5.2.2.5. Africa
    - 5.2.2.6. South America
- 5.3. Product Comparison Matrix
  - 5.3.1. Specifications
  - 5.3.2. Market Positioning
  - 5.3.3. Pricing
6. Global AI in Clinical Trials Market Analysis, by Component
- 6.1. Key Segment Analysis
- 6.2. AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, by Component, 2021-2035
  - 6.2.1. Software
    - 6.2.1.1. Clinical Trial Management Software
    - 6.2.1.2. Patient Recruitment & Enrollment Software
    - 6.2.1.3. Clinical Data Management Software
    - 6.2.1.4. Trial Analytics & Predictive Modeling Software
    - 6.2.1.5. Safety & Pharmacovigilance Software
    - 6.2.1.6. Regulatory Compliance Software
    - 6.2.1.7. Others
  - 6.2.2. Hardware
    - 6.2.2.1. AI Servers & High-Performance Computing (HPC) Systems
    - 6.2.2.2. Data Storage Systems
    - 6.2.2.3. Clinical Data Capture Devices
    - 6.2.2.4. Networking & Communication Infrastructure
    - 6.2.2.5. Workstations & Mobile Devices
    - 6.2.2.6. Others
  - 6.2.3. Services
    - 6.2.3.1. AI Consulting & System Integration Services
    - 6.2.3.2. AI Deployment & Managed Services
    - 6.2.3.3. Clinical Data Analytics Services
    - 6.2.3.4. Regulatory & Compliance Services
    - 6.2.3.5. Technical Support & Training Services
    - 6.2.3.6. Others
7. Global AI in Clinical Trials Market Analysis, by Technology
- 7.1. Key Segment Analysis
- 7.2. AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology, 2021-2035
  - 7.2.1. Machine Learning (ML)
  - 7.2.2. Deep Learning
  - 7.2.3. Natural Language Processing (NLP)
  - 7.2.4. Computer Vision
  - 7.2.5. Predictive Analytics
  - 7.2.6. Generative AI
  - 7.2.7. Robotic Process Automation (RPA)
  - 7.2.8. Big Data Analytics
  - 7.2.9. Others
8. Global AI in Clinical Trials Market Analysis, by Deployment Mode
- 8.1. Key Segment Analysis
- 8.2. AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, by Deployment Mode, 2021-2035
  - 8.2.1. Cloud-Based
  - 8.2.2. On-Premises
  - 8.2.3. Hybrid
9. Global AI in Clinical Trials Market Analysis, by Clinical Trial Phase
- 9.1. Key Segment Analysis
- 9.2. AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, by Clinical Trial Phase, 2021-2035
  - 9.2.1. Phase I
  - 9.2.2. Phase II
  - 9.2.3. Phase III
  - 9.2.4. Phase IV
10. Global AI in Clinical Trials Market Analysis, by Therapeutic Area
- 10.1. Key Segment Analysis
- 10.2. AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Area, 2021-2035
  - 10.2.1. Oncology
  - 10.2.2. Cardiovascular Diseases
  - 10.2.3. Neurology
  - 10.2.4. Infectious Diseases
  - 10.2.5. Immunology
  - 10.2.6. Endocrinology
  - 10.2.7. Respiratory Diseases
  - 10.2.8. Rare Diseases
  - 10.2.9. Gastroenterology
  - 10.2.10. Dermatology
  - 10.2.11. Others
11. Global AI in Clinical Trials Market Analysis, by Application
- 11.1. Key Segment Analysis
- 11.2. AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
  - 11.2.1. Clinical Trial Design
  - 11.2.2. Patient Recruitment & Enrollment
  - 11.2.3. Patient Matching
  - 11.2.4. Site Selection & Feasibility
  - 11.2.5. Clinical Data Management
  - 11.2.6. Clinical Trial Monitoring
  - 11.2.7. Risk-Based Monitoring
  - 11.2.8. Protocol Optimization
  - 11.2.9. Adverse Event Detection
  - 11.2.10. Regulatory Compliance
  - 11.2.11. Drug Safety & Pharmacovigilance
  - 11.2.12. Trial Outcome Prediction
  - 11.2.13. Others
12. Global AI in Clinical Trials Market Analysis, by End User
- 12.1. Key Segment Analysis
- 12.2. AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
  - 12.2.1. Pharmaceutical Companies
  - 12.2.2. Biotechnology Companies
  - 12.2.3. Contract Research Organizations (CROs)
  - 12.2.4. Academic & Research Institutes
  - 12.2.5. Hospitals & Clinical Research Centers
  - 12.2.6. Government Organizations
  - 12.2.7. Others
13. Global AI in Clinical Trials Market Analysis and Forecasts, by Region
- 13.1. Key Findings
- 13.2. AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
  - 13.2.1. North America
  - 13.2.2. Europe
  - 13.2.3. Asia Pacific
  - 13.2.4. Middle East
  - 13.2.5. Africa
  - 13.2.6. South America
14. North America AI in Clinical Trials Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. North America AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 14.3.1. Component
  - 14.3.2. Technology
  - 14.3.3. Deployment Mode
  - 14.3.4. Clinical Trial Phase
  - 14.3.5. Therapeutic Area
  - 14.3.6. Application
  - 14.3.7. End User
  - 14.3.8. Country
    - 14.3.8.1. USA
    - 14.3.8.2. Canada
    - 14.3.8.3. Mexico
- 14.4. USA AI in Clinical Trials Market
  - 14.4.1. Country Segmental Analysis
  - 14.4.2. Component
  - 14.4.3. Technology
  - 14.4.4. Deployment Mode
  - 14.4.5. Clinical Trial Phase
  - 14.4.6. Therapeutic Area
  - 14.4.7. Application
  - 14.4.8. End User
- 14.5. Canada AI in Clinical Trials Market
  - 14.5.1. Country Segmental Analysis
  - 14.5.2. Component
  - 14.5.3. Technology
  - 14.5.4. Deployment Mode
  - 14.5.5. Clinical Trial Phase
  - 14.5.6. Therapeutic Area
  - 14.5.7. Application
  - 14.5.8. End User
- 14.6. Mexico AI in Clinical Trials Market
  - 14.6.1. Country Segmental Analysis
  - 14.6.2. Component
  - 14.6.3. Technology
  - 14.6.4. Deployment Mode
  - 14.6.5. Clinical Trial Phase
  - 14.6.6. Therapeutic Area
  - 14.6.7. Application
  - 14.6.8. End User
15. Europe AI in Clinical Trials Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Europe AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 15.3.1. Component
  - 15.3.2. Technology
  - 15.3.3. Deployment Mode
  - 15.3.4. Clinical Trial Phase
  - 15.3.5. Therapeutic Area
  - 15.3.6. Application
  - 15.3.7. End User
  - 15.3.8. Country
    - 15.3.8.1. Germany
    - 15.3.8.2. United Kingdom
    - 15.3.8.3. France
    - 15.3.8.4. Italy
    - 15.3.8.5. Spain
    - 15.3.8.6. Netherlands
    - 15.3.8.7. Nordic Countries
    - 15.3.8.8. Poland
    - 15.3.8.9. Russia & CIS
    - 15.3.8.10. Rest of Europe
- 15.4. Germany AI in Clinical Trials Market
  - 15.4.1. Country Segmental Analysis
  - 15.4.2. Component
  - 15.4.3. Technology
  - 15.4.4. Deployment Mode
  - 15.4.5. Clinical Trial Phase
  - 15.4.6. Therapeutic Area
  - 15.4.7. Application
  - 15.4.8. End User
- 15.5. United Kingdom AI in Clinical Trials Market
  - 15.5.1. Country Segmental Analysis
  - 15.5.2. Component
  - 15.5.3. Technology
  - 15.5.4. Deployment Mode
  - 15.5.5. Clinical Trial Phase
  - 15.5.6. Therapeutic Area
  - 15.5.7. Application
  - 15.5.8. End User
- 15.6. France AI in Clinical Trials Market
  - 15.6.1. Country Segmental Analysis
  - 15.6.2. Component
  - 15.6.3. Technology
  - 15.6.4. Deployment Mode
  - 15.6.5. Clinical Trial Phase
  - 15.6.6. Therapeutic Area
  - 15.6.7. Application
  - 15.6.8. End User
- 15.7. Italy AI in Clinical Trials Market
  - 15.7.1. Country Segmental Analysis
  - 15.7.2. Component
  - 15.7.3. Technology
  - 15.7.4. Deployment Mode
  - 15.7.5. Clinical Trial Phase
  - 15.7.6. Therapeutic Area
  - 15.7.7. Application
  - 15.7.8. End User
- 15.8. Spain AI in Clinical Trials Market
  - 15.8.1. Country Segmental Analysis
  - 15.8.2. Component
  - 15.8.3. Technology
  - 15.8.4. Deployment Mode
  - 15.8.5. Clinical Trial Phase
  - 15.8.6. Therapeutic Area
  - 15.8.7. Application
  - 15.8.8. End User
- 15.9. Netherlands AI in Clinical Trials Market
  - 15.9.1. Country Segmental Analysis
  - 15.9.2. Component
  - 15.9.3. Technology
  - 15.9.4. Deployment Mode
  - 15.9.5. Clinical Trial Phase
  - 15.9.6. Therapeutic Area
  - 15.9.7. Application
  - 15.9.8. End User
- 15.10. Nordic Countries AI in Clinical Trials Market
  - 15.10.1. Country Segmental Analysis
  - 15.10.2. Component
  - 15.10.3. Technology
  - 15.10.4. Deployment Mode
  - 15.10.5. Clinical Trial Phase
  - 15.10.6. Therapeutic Area
  - 15.10.7. Application
  - 15.10.8. End User
- 15.11. Poland AI in Clinical Trials Market
  - 15.11.1. Country Segmental Analysis
  - 15.11.2. Component
  - 15.11.3. Technology
  - 15.11.4. Deployment Mode
  - 15.11.5. Clinical Trial Phase
  - 15.11.6. Therapeutic Area
  - 15.11.7. Application
  - 15.11.8. End User
- 15.12. Russia & CIS AI in Clinical Trials Market
  - 15.12.1. Country Segmental Analysis
  - 15.12.2. Component
  - 15.12.3. Technology
  - 15.12.4. Deployment Mode
  - 15.12.5. Clinical Trial Phase
  - 15.12.6. Therapeutic Area
  - 15.12.7. Application
  - 15.12.8. End User
- 15.13. Rest of Europe AI in Clinical Trials Market
  - 15.13.1. Country Segmental Analysis
  - 15.13.2. Component
  - 15.13.3. Technology
  - 15.13.4. Deployment Mode
  - 15.13.5. Clinical Trial Phase
  - 15.13.6. Therapeutic Area
  - 15.13.7. Application
  - 15.13.8. End User
16. Asia Pacific AI in Clinical Trials Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Asia Pacific AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 16.3.1. Component
  - 16.3.2. Technology
  - 16.3.3. Deployment Mode
  - 16.3.4. Clinical Trial Phase
  - 16.3.5. Therapeutic Area
  - 16.3.6. Application
  - 16.3.7. End User
  - 16.3.8. Country
    - 16.3.8.1. China
    - 16.3.8.2. India
    - 16.3.8.3. Japan
    - 16.3.8.4. South Korea
    - 16.3.8.5. Australia and New Zealand
    - 16.3.8.6. Indonesia
    - 16.3.8.7. Malaysia
    - 16.3.8.8. Thailand
    - 16.3.8.9. Vietnam
    - 16.3.8.10. Rest of Asia Pacific
- 16.4. China AI in Clinical Trials Market
  - 16.4.1. Country Segmental Analysis
  - 16.4.2. Component
  - 16.4.3. Technology
  - 16.4.4. Deployment Mode
  - 16.4.5. Clinical Trial Phase
  - 16.4.6. Therapeutic Area
  - 16.4.7. Application
  - 16.4.8. End User
- 16.5. India AI in Clinical Trials Market
  - 16.5.1. Country Segmental Analysis
  - 16.5.2. Component
  - 16.5.3. Technology
  - 16.5.4. Deployment Mode
  - 16.5.5. Clinical Trial Phase
  - 16.5.6. Therapeutic Area
  - 16.5.7. Application
  - 16.5.8. End User
- 16.6. Japan AI in Clinical Trials Market
  - 16.6.1. Country Segmental Analysis
  - 16.6.2. Component
  - 16.6.3. Technology
  - 16.6.4. Deployment Mode
  - 16.6.5. Clinical Trial Phase
  - 16.6.6. Therapeutic Area
  - 16.6.7. Application
  - 16.6.8. End User
- 16.7. South Korea AI in Clinical Trials Market
  - 16.7.1. Country Segmental Analysis
  - 16.7.2. Component
  - 16.7.3. Technology
  - 16.7.4. Deployment Mode
  - 16.7.5. Clinical Trial Phase
  - 16.7.6. Therapeutic Area
  - 16.7.7. Application
  - 16.7.8. End User
- 16.8. Australia and New Zealand AI in Clinical Trials Market
  - 16.8.1. Country Segmental Analysis
  - 16.8.2. Component
  - 16.8.3. Technology
  - 16.8.4. Deployment Mode
  - 16.8.5. Clinical Trial Phase
  - 16.8.6. Therapeutic Area
  - 16.8.7. Application
  - 16.8.8. End User
- 16.9. Indonesia AI in Clinical Trials Market
  - 16.9.1. Country Segmental Analysis
  - 16.9.2. Component
  - 16.9.3. Technology
  - 16.9.4. Deployment Mode
  - 16.9.5. Clinical Trial Phase
  - 16.9.6. Therapeutic Area
  - 16.9.7. Application
  - 16.9.8. End User
- 16.10. Malaysia AI in Clinical Trials Market
  - 16.10.1. Country Segmental Analysis
  - 16.10.2. Component
  - 16.10.3. Technology
  - 16.10.4. Deployment Mode
  - 16.10.5. Clinical Trial Phase
  - 16.10.6. Therapeutic Area
  - 16.10.7. Application
  - 16.10.8. End User
- 16.11. Thailand AI in Clinical Trials Market
  - 16.11.1. Country Segmental Analysis
  - 16.11.2. Component
  - 16.11.3. Technology
  - 16.11.4. Deployment Mode
  - 16.11.5. Clinical Trial Phase
  - 16.11.6. Therapeutic Area
  - 16.11.7. Application
  - 16.11.8. End User
- 16.12. Vietnam AI in Clinical Trials Market
  - 16.12.1. Country Segmental Analysis
  - 16.12.2. Component
  - 16.12.3. Technology
  - 16.12.4. Deployment Mode
  - 16.12.5. Clinical Trial Phase
  - 16.12.6. Therapeutic Area
  - 16.12.7. Application
  - 16.12.8. End User
- 16.13. Rest of Asia Pacific AI in Clinical Trials Market
  - 16.13.1. Country Segmental Analysis
  - 16.13.2. Component
  - 16.13.3. Technology
  - 16.13.4. Deployment Mode
  - 16.13.5. Clinical Trial Phase
  - 16.13.6. Therapeutic Area
  - 16.13.7. Application
  - 16.13.8. End User
17. Middle East AI in Clinical Trials Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Middle East AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 17.3.1. Component
  - 17.3.2. Technology
  - 17.3.3. Deployment Mode
  - 17.3.4. Clinical Trial Phase
  - 17.3.5. Therapeutic Area
  - 17.3.6. Application
  - 17.3.7. End User
  - 17.3.8. Country
    - 17.3.8.1. Turkey
    - 17.3.8.2. UAE
    - 17.3.8.3. Saudi Arabia
    - 17.3.8.4. Israel
    - 17.3.8.5. Rest of Middle East
- 17.4. Turkey AI in Clinical Trials Market
  - 17.4.1. Country Segmental Analysis
  - 17.4.2. Component
  - 17.4.3. Technology
  - 17.4.4. Deployment Mode
  - 17.4.5. Clinical Trial Phase
  - 17.4.6. Therapeutic Area
  - 17.4.7. Application
  - 17.4.8. End User
- 17.5. UAE AI in Clinical Trials Market
  - 17.5.1. Country Segmental Analysis
  - 17.5.2. Component
  - 17.5.3. Technology
  - 17.5.4. Deployment Mode
  - 17.5.5. Clinical Trial Phase
  - 17.5.6. Therapeutic Area
  - 17.5.7. Application
  - 17.5.8. End User
- 17.6. Saudi Arabia AI in Clinical Trials Market
  - 17.6.1. Country Segmental Analysis
  - 17.6.2. Component
  - 17.6.3. Technology
  - 17.6.4. Deployment Mode
  - 17.6.5. Clinical Trial Phase
  - 17.6.6. Therapeutic Area
  - 17.6.7. Application
  - 17.6.8. End User
- 17.7. Israel AI in Clinical Trials Market
  - 17.7.1. Country Segmental Analysis
  - 17.7.2. Component
  - 17.7.3. Technology
  - 17.7.4. Deployment Mode
  - 17.7.5. Clinical Trial Phase
  - 17.7.6. Therapeutic Area
  - 17.7.7. Application
  - 17.7.8. End User
- 17.8. Rest of Middle East AI in Clinical Trials Market
  - 17.8.1. Country Segmental Analysis
  - 17.8.2. Component
  - 17.8.3. Technology
  - 17.8.4. Deployment Mode
  - 17.8.5. Clinical Trial Phase
  - 17.8.6. Therapeutic Area
  - 17.8.7. Application
  - 17.8.8. End User
18. Africa AI in Clinical Trials Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Africa AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 18.3.1. Component
  - 18.3.2. Technology
  - 18.3.3. Deployment Mode
  - 18.3.4. Clinical Trial Phase
  - 18.3.5. Therapeutic Area
  - 18.3.6. Application
  - 18.3.7. End User
  - 18.3.8. Country
    - 18.3.8.1. South Africa
    - 18.3.8.2. Egypt
    - 18.3.8.3. Nigeria
    - 18.3.8.4. Algeria
    - 18.3.8.5. Rest of Africa
- 18.4. South Africa AI in Clinical Trials Market
  - 18.4.1. Country Segmental Analysis
  - 18.4.2. Component
  - 18.4.3. Technology
  - 18.4.4. Deployment Mode
  - 18.4.5. Clinical Trial Phase
  - 18.4.6. Therapeutic Area
  - 18.4.7. Application
  - 18.4.8. End User
- 18.5. Egypt AI in Clinical Trials Market
  - 18.5.1. Country Segmental Analysis
  - 18.5.2. Component
  - 18.5.3. Technology
  - 18.5.4. Deployment Mode
  - 18.5.5. Clinical Trial Phase
  - 18.5.6. Therapeutic Area
  - 18.5.7. Application
  - 18.5.8. End User
- 18.6. Nigeria AI in Clinical Trials Market
  - 18.6.1. Country Segmental Analysis
  - 18.6.2. Component
  - 18.6.3. Technology
  - 18.6.4. Deployment Mode
  - 18.6.5. Clinical Trial Phase
  - 18.6.6. Therapeutic Area
  - 18.6.7. Application
  - 18.6.8. End User
- 18.7. Algeria AI in Clinical Trials Market
  - 18.7.1. Country Segmental Analysis
  - 18.7.2. Component
  - 18.7.3. Technology
  - 18.7.4. Deployment Mode
  - 18.7.5. Clinical Trial Phase
  - 18.7.6. Therapeutic Area
  - 18.7.7. Application
  - 18.7.8. End User
- 18.8. Rest of Africa AI in Clinical Trials Market
  - 18.8.1. Country Segmental Analysis
  - 18.8.2. Component
  - 18.8.3. Technology
  - 18.8.4. Deployment Mode
  - 18.8.5. Clinical Trial Phase
  - 18.8.6. Therapeutic Area
  - 18.8.7. Application
  - 18.8.8. End User
19. South America AI in Clinical Trials Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. South America AI in Clinical Trials Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 19.3.1. Component
  - 19.3.2. Technology
  - 19.3.3. Deployment Mode
  - 19.3.4. Clinical Trial Phase
  - 19.3.5. Therapeutic Area
  - 19.3.6. Application
  - 19.3.7. End User
  - 19.3.8. Country
    - 19.3.8.1. Brazil
    - 19.3.8.2. Argentina
    - 19.3.8.3. Rest of South America
- 19.4. Brazil AI in Clinical Trials Market
  - 19.4.1. Country Segmental Analysis
  - 19.4.2. Component
  - 19.4.3. Technology
  - 19.4.4. Deployment Mode
  - 19.4.5. Clinical Trial Phase
  - 19.4.6. Therapeutic Area
  - 19.4.7. Application
  - 19.4.8. End User
- 19.5. Argentina AI in Clinical Trials Market
  - 19.5.1. Country Segmental Analysis
  - 19.5.2. Component
  - 19.5.3. Technology
  - 19.5.4. Deployment Mode
  - 19.5.5. Clinical Trial Phase
  - 19.5.6. Therapeutic Area
  - 19.5.7. Application
  - 19.5.8. End User
- 19.6. Rest of South America AI in Clinical Trials Market
  - 19.6.1. Country Segmental Analysis
  - 19.6.2. Component
  - 19.6.3. Technology
  - 19.6.4. Deployment Mode
  - 19.6.5. Clinical Trial Phase
  - 19.6.6. Therapeutic Area
  - 19.6.7. Application
  - 19.6.8. End User
20. Key Players/ Company Profile
- 20.1. Amazon Web Services, Inc.
  - 20.1.1. Company Details/ Overview
  - 20.1.2. Company Financials
  - 20.1.3. Key Customers and Competitors
  - 20.1.4. Business/ Industry Portfolio
  - 20.1.5. Product Portfolio/ Specification Details
  - 20.1.6. Pricing Data
  - 20.1.7. Strategic Overview
  - 20.1.8. Recent Developments
- 20.2. Clario
- 20.3. ConcertAI, LLC
- 20.4. ICON plc
- 20.5. International Business Machines Corporation (IBM)
- 20.6. IQVIA Inc.
- 20.7. Laboratory Corporation of America Holdings (Labcorp)
- 20.8. Medidata Solutions, Inc.
- 20.9. NVIDIA Corporation
- 20.10. Oracle Corporation
- 20.11. Parexel International Corporation
- 20.12. Saama Technologies, LLC
- 20.13. Syneos Health, Inc.
- 20.14. Tempus AI, Inc.
- 20.15. Unlearn AI, Inc.
- 20.16. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF

PRICING DETAILS

Single-User Upto 2 Users - [PDF + Excel Only]

USD 4150

Multi-User Upto 10 Users - [PDF + Excel + PPT]

USD 5950

Enterprise-User Company-wide - [Report Pack + Benchmark + 6M Update]

USD 7750

Related Report

Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation